Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment
Luca Mastorino, Paolo Dapavo, Sara Susca, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2023) Vol. 22, Iss. 1, pp. 34-42
Open Access | Times Cited: 20

Showing 20 citing articles:

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Sarah E. Thomas, Liana Barenbrug, Gerjon Hannink, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 565-578
Open Access | Times Cited: 11
Efficacy of probiotic supplementation in the treatment of psoriasis—A systematic review and meta‐analysis
Kebo Wei, Xiaoshu Liao, Tianlin Yang, et al.
Journal of Cosmetic Dermatology (2024) Vol. 23, Iss. 7, pp. 2361-2367
Open Access | Times Cited: 7
Psoriasis severity in moderate to severe psoriatic Greek patients routinely treated with systemic treatment: a cross-sectional and retrospective chart review study (CRYSTAL-Greece)
Dimitrios Rigopoulos, John Katsantonis, O. Neofotistou, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy
Federico Pirrò, Giacomo Caldarola, Nicoletta Bernardini, et al.
Dermatology Practical & Conceptual (2025) Vol. 15, Iss. 1, pp. 4838-4838
Open Access
Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing
Luca Mastorino, Paolo Dapavo, Michela Ortoncelli, et al.
Experimental Dermatology (2025) Vol. 34, Iss. 2
Open Access
Risk of HBV reactivation in psoriasis vulgaris patients receiving biological agent therapy
Ayşegül Tel Kankılıç, Ömer Karakoyun, Erhan Ayhan
Cutaneous and Ocular Toxicology (2025), pp. 1-5
Closed Access
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study
Giovanni Fiorillo, Luciano Ibba, Luigi Gargiulo, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 2, pp. 186-186
Open Access | Times Cited: 3
Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States
Maryia Zhdanava, Timothy Fitzgerald, Dominic Pilon, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 2
Drug Survival and Clinical Course of Patients with Cancer Treated with Biologic Therapy for Psoriasis
Nicole Macagno, Luca Mastorino, Michela Ortoncelli, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6546-6546
Open Access | Times Cited: 2
Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience
Silvia Giordano, Paolo Dapavo, Michela Ortoncelli, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 24, pp. 7503-7503
Open Access | Times Cited: 5
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies
April W. Armstrong, Álvaro González‐Cantero, Saakshi Khattri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 933-952
Open Access | Times Cited: 1
Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)
Diego Orsini, Chiara Assorgi, Claudio Bonifati, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis
Chang‐Yu Hsieh, Francis Li‐Tien Hsu, Tsen‐Fang Tsai
Dermatology and Therapy (2024) Vol. 14, Iss. 9, pp. 2607-2620
Open Access | Times Cited: 1
IFN-γ, IL-17A, IL-4, and IL-13: Potential Biomarkers for Prediction of the Effectiveness of Biologics in Psoriasis Patients
Ching‐Liang Hsieh, Sheng‐Jie Yu, Kuo‐Lung Lai, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1115-1115
Open Access
Real-Life Comparative Effectiveness of IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Multicenter Experience
Alessandro Borghi, Giulia Odorici, Federico Bardazzi, et al.
Dermatology Practical & Conceptual (2024), pp. e2024179-e2024179
Open Access
Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia
Ahmad Alamer, Wejdan Alyazidi, Saad A. Aldosari, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access
Real‐World Experience of Secukinumab Treatment in Patients with Moderate‐to‐Severe Plaque Psoriasis in Greece: 3‐Year Interim Results of the SERENA Study
D. Ioannides, Dimitrios Rigopoulos, Markos Papakonstantis, et al.
Dermatologic Therapy (2024) Vol. 2024, Iss. 1
Open Access
Editorial: Patients-oriented treatments for chronic inflammatory skin diseases
Luca Mastorino, Simone Ribero, Martina Burlando, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access
Revisiting risankizumab: a newer biologic drug in dermatology
Aditya K Bubna, Vinayak Viplav
Italian Journal of Dermatology and Venereology (2024) Vol. 159, Iss. 5
Closed Access
Psoriasis in Childbearing Age: A Real-Life, Retrospective, Single-Center Study on Anti-IL17 and IL-23 Agents
Silvia Borriello, Gabriele Roccuzzo, Paolo Dapavo, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6401-6401
Open Access
Page 1

Scroll to top